Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7949962 | 0.74 | SMN1; SMN2 (0.52) | KDM4EALDH1A1MEN1GAAHPGD | |
| SCHEMBL8169596 | 0.71 | HSD17B10 (0.42) | KDM4EMAPTALDH1A1GAAHPGD | |
| SCHEMBL7593716 | 0.70 | GRIA1 (0.61) | KDM4EMAPTL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL8634867 | 0.70 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7948487 | 0.70 | HSD17B10 (0.44) | KDM4EMAPTALDH1A1GAAHPGD | |
| SCHEMBL7529844 | 0.67 | KDM4E (0.44) | KDM4EMAPTL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL7957683 | 0.66 | GRIN2D (0.50) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8037105 | 0.66 | CFB (0.48) | KDM4EMAPTL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL8040463 | 0.65 | CFB (0.50) | KDM4EMAPTL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL8037118 | 0.65 | CFB (0.50) | KDM4EMAPTL3MBTL1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0837854-B1 | ALKYL AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-0830348-B1 | CYCLIC AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6110911-A | ADMINISTERING NEUROPROTECTANT/ANTICONVULSANT TO PATIENT | WARNER-LAMBERT COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| US-5874426-A | USEFUL IN THE TREATMENT OF STROKE, CEREBRAL ISCHEMIA, OR CEREBRAL INFARCTION RESULTING FROM THROMBOEMBOLIC OR HEMORRHAGIC STROKE, CEREBRAL VASOSPASMS, HYPOGLYCEMIA, CARDIAC ARREST, STATUS EPILEPTICUS, ANOXIA, SEIZURE DISORDER | WARNER-LAMBERT COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0837854-A1 | ALKYL AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0830348-A1 | CYCLIC AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-03-25 | — | — | EP | disclosed |
| US-5654303-A | FOR TREATING NERVOUS SYSTEM OR CARDIOVASCULAR SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996040650-A1 | CYCLIC AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040651-A1 | ALKYL AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |